Navigation Links
Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel

MONROVIA, Calif., Sept. 2, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Debra Zack, M.D., Ph.D., vice president, clinical development and the appointment of Lloyd Rowland, senior vice president, chief compliance officer and general counsel.

"Debra's expertise in biologics clinical development and medical affairs will be of great value to Xencor as we anticipate advancing the clinical development of XmAb5871® and XmAb7195®, and as we progress to the clinic with our lead bispecific candidates," said Bassil Dahiyat Ph.D., president and CEO of Xencor. "And Lloyd brings a wealth of legal, compliance and governance experience working with public companies and is an important addition to the team in our current stage of rapid growth. Their collective experience addresses critical needs and will be of increasing importance as our clinical pipeline steadily grows."  

Dr. Zack joins Xencor with more than a decade of experience in drug development. Prior to joining Xencor, Dr. Zack was executive director, medical scientific leader at Novartis Institute for Biological Research where she provided guidance in translational medicine for early project teams in rheumatology and regenerative medicine.  Before that, she had a long career at Amgen in various pre-clinical, clinical development, and medical affairs roles, most recently as the executive director, global development lead for Enbrel and executive director, global product area lead for rheumatology and dermatology. She earned her bachelor's degree in math and chemistry from Texas Christian University and earned her medical and doctoral degrees from University of Texas Southwestern Medical and Graduate School.

Mr. Rowland has more than two decades of biotechnology and pharmaceutical industry legal counsel and transactional experience. Prior to joining Xencor, Mr. Rowland served at Amylin Pharmaceuticals for twelve years, most recently as vice president and chief compliance officer and formerly, as general counsel and secretary. Earlier in his career, he served as vice president, secretary and general counsel for Alliance Pharmaceutical Corp. Mr. Rowland earned his bachelor's degree in economics and political science from Southern Methodist University, and earned his juris doctor from Emory University School of Law.

About Xencor, Inc.

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Currently, seven candidates are in clinical development internally and with partners that have been engineered with Xencor's XmAb® technology. Xencor's internally-discovered programs include XmAb5871, in Phase 1b/2a clinical trials for the treatment of Rheumatoid arthritis and lupus, XmAb7195 in Phase 1 development for the treatment of asthma, and XmAb5574/MOR208 which has been licensed to Morphosys AG and is in Phase 2 clinical trials for the treatment of acute lymphoblastic leukemia and non-Hodgkin lymphoma. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Amgen, Merck, Janssen R&D LLC, Alexion and Boehringer Ingelheim.

For more information, please visit

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the U.S. securities laws, including statements associated with Xencor's research and its expectations regarding  future therapeutic and commercial potential of Xencor's technologies, programs, drug candidates and intellectual property related to Xencor's XmAb technology.  Because such statements are subject to risks and uncertainties, including risks associated with the process of discovering, developing and commercializing drugs that are safe and effective, actual results and the timing of events may differ materially from those expressed or implied by such forward-looking statements.  These and other risks concerning Xencor's programs and technology are described in additional detail in Xencor's SEC filings.  These forward-looking statements speak as of the date on which they were made, are based upon Xencor's current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Xencor disclaims any intention or obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SOURCE Xencor, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related biology technology :

1. Xencor Prices Initial Public Offering
2. Xencors XmAb5871 Enters Phase 2a Study for Autoimmune Disease
3. Lycera Appoints Harinder Singh, Ph.D., as Chair of Scientific Advisory Board
4. Thesan Pharmaceuticals Appoints Dr. Bhaskar Chaudhuri to the Board of Directors August 2014
5. CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board
6. Epic Sciences Appoints Greg Lucier as Chairman of the Board of Directors
7. AuraSense Therapeutics Appoints Biotechnology Veteran David S. Snyder as Chief Financial Officer
8. Neurotrope Board of Directors Appoints Chairmen Ramat and Freiman as Interim Co-CEOs
9. DuPont Tate & Lyle Bio Products Appoints Lipscomb Chemical as Distributor for Zemea® USP
10. Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors
11. Spherix Appoints Richard Cohen as Chief Financial Officer
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... International Society for ... of the premier annual events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference ... ISPE hosted the largest number of attendees in more than a decade. ...
(Date:11/24/2015)... -- --> --> ... Market by Product & Services (Primer, Probe, Custom Oligos, ... End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) - Global ... expected to reach USD 1,918.6 Million by 2020 from ... 10.1% during the forecast period. Browse 183 ...
(Date:11/24/2015)... SHPG ) announced today that Jeff Poulton , Chief ... Annual Healthcare Conference in New York City , ... p.m. GMT). --> SHPG ) announced today that ... Jaffray 27 th Annual Healthcare Conference in New ... 8:30 a.m. EST (1:30 p.m. GMT). --> Shire plc ...
(Date:11/24/2015)... , Nov. 24, 2015 /PRNewswire/ - Aeterna Zentaris ... today that the remaining 11,000 post-share consolidation (or ... Warrants (the "Series B Warrants") subject to the ... on November 23, 2015, which will result in ... giving effect to the issuance of such shares, ...
Breaking Biology Technology:
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... , Oct. 29, 2015  Rubicon Genomics, ... for U.S. distribution of its DNA library preparation ... and Rubicon,s new ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq ... the preparation of NGS libraries for liquid biopsies--the ... diagnostic and prognostic applications in cancer and other ...
(Date:10/27/2015)... , October 27, 2015 ... Automated Semantic Gaze Mapping technology (ASGM) automatically maps data ... Eye Tracking Glasses , so that they can ... --> Munich, Germany , October ... automatically maps data from mobile eye tracking videos created ...
Breaking Biology News(10 mins):